Average Price Target AU$329.07 ▲(18.72% Upside) eyJuYXZpZ2F0b3IiOnsiZGlzYWJsZWQiOnRydWV9LCJleHBvcnRpbmciOnsiZW5hYmxlZCI6ZmFsc2V9LCJ0aXRsZSI6eyJ0ZXh0IjpudWxsfSwiY2hhcnQiOnsiaGVpZ2h0IjoyMDAsInN0eWxlIjp7ImZvbnRGYW1pbHkiOiJSb2JvdG8gRmxleCIsImZvbnRXZWlnaHQiOiI0MDAiLCJjb2xvciI6IiM1ZDV...
Jarden Research Adjusts CSL’s Price Target to AU$298.57 From AU$316.16, Keeps at Overweight 24-02-12 MT More recommendations Press Releases: CSL Limited CSL : Shareholder Information Meetings (Sydney & Brisbane) ASX Announcement & Presentation May. 05 PU CSL : Shareholder Information Meeti...
Federal Drugs Administration's advisory committee that recommends CSL vaccines Gardasil and Cervarix. Moreover, it states that UBS maintains its buy at 42.18 dollars target price. A graph showing the share price of CSL and S&P/ASX 200 from September 2006 to 2009 is also included....
CSL Seqirus is part ofCSL Limited(ASX: CSL). As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic prepa...
The transaction, has been unanimously approved by both companies’ Boards of Directors. The offer price for each registered share of Vifor Pharma Ltd. is USD 179.25 in cash. The public tender offer is subject to the offer conditions set forth in the offer prospectus, which includes the report...